Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Diseases

Free Subscription Articles published in Cancer Retrieve available abstracts of 49 articles: HTML format

Single Articles

August 2024
1. VAN NOESEL MM
   Rare pediatric tumors benefit from large clinical trials: The story of undifferentiated embryonal sarcoma of the liver.
   Cancer. 2024;130:2582-2585.
   PubMed    
   
   
   
2. AWAD A, Pal K, Yevich S, Kuban JD, et al
   Safety and efficacy of percutaneous image-guided ablation for soft tissue sarcoma metastases to the liver.
   Cancer. 2024;130:2703-2712.
   PubMed     Abstract available
   
   
   
3. SPUNT SL, Xue W, Gao Z, Hayes Dixon A, et al
   Embryonal sarcoma of the liver in pediatric and young adult patients: A report from Children's Oncology Group study ARST0332.
   Cancer. 2024;130:2683-2693.
   PubMed     Abstract available
   
   
   May 2024
4. NING T, Li D, Deng T, Bai Y, et al
   Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
   Cancer. 2024 May 23. doi: 10.1002/cncr.35377.
   PubMed     Abstract available
   
   
   
5. NIERENGARTEN MB
   Global phase 3 results show that bevacizumab with immunotherapy has activity in liver cancer.
   Cancer. 2024;130:1547-1548.
   PubMed    
   
   
   February 2024
6. CONNOLLY GK, Harris RD, Shumate C, Rednam SP, et al
   Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: A population-based assessment in seven million children.
   Cancer. 2024;130:467-475.
   PubMed     Abstract available
   
   
   January 2024
7. PORTA C, Negri F, Cosmai L
   Hepatocellular carcinoma, vascular endothelial growth factor receptors-targeting agents, and hypertension: A much more complicated relationship than expected.
   Cancer. 2024 Jan 27. doi: 10.1002/cncr.35218.
   PubMed    
   
   
   
8. PISCAGLIA F, Ikeda K, Cheng AL, Kudo M, et al
   Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
   Cancer. 2024 Jan 23. doi: 10.1002/cncr.35185.
   PubMed     Abstract available
   
   
   
9. COLLOCA GA, Venturino A
   Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial-level analysis.
   Cancer. 2024 Jan 17. doi: 10.1002/cncr.35199.
   PubMed     Abstract available
   
   
   November 2023
10. ACUNA N, Zhou K, Pinheiro PS, Cheng I, et al
    Increasing risk of hepatocellular carcinoma with successive generations in the United States among Mexican American adults: The Multiethnic Cohort.
    Cancer. 2023 Nov 20. doi: 10.1002/cncr.35000.
    PubMed     Abstract available
    
    
    
11. WONG EC, Lupo PJ, Desrosiers TA, Nichols HB, et al
    Associations between birth defects with neural crest cell origins and pediatric embryonal tumors.
    Cancer. 2023;129:3595-3602.
    PubMed     Abstract available
    
    
    
12. 
    Erratum to "Association between posttreatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma".
    Cancer. 2023 Nov 4. doi: 10.1002/cncr.35102.
    PubMed    
    
    
    October 2023
13. HALLEMEIER CL, Sharma N, Anker C, Selfridge JE, et al
    American Radium Society Appropriate Use Criteria for the use of liver-directed therapies for nonsurgical management of liver metastases: Systematic review and guidelines.
    Cancer. 2023;129:3193-3212.
    PubMed     Abstract available
    
    
    August 2023
14. 
    Erratum to "Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013".
    Cancer. 2023 Aug 1. doi: 10.1002/cncr.34961.
    PubMed    
    
    
    July 2023
15. BUSH DA, Volk M, Smith JC, Reeves ME, et al
    Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial.
    Cancer. 2023 Jul 28. doi: 10.1002/cncr.34965.
    PubMed     Abstract available
    
    
    
16. CAI QY, Yang P, Yang XL, Zhang XH, et al
    The association of carbohydrate antigen 19-9 response with radiologic response and survival in intrahepatic cholangiocarcinoma: A prospective cohort study.
    Cancer. 2023 Jul 14. doi: 10.1002/cncr.34854.
    PubMed     Abstract available
    
    
    
17. CHEN Q, Wang X, Zheng Y, Ye T, et al
    Cancer-associated fibroblasts contribute to the immunosuppressive landscape and influence the efficacy of the combination therapy of PD-1 inhibitors and antiangiogenic agents in hepatocellular carcinoma.
    Cancer. 2023 Jul 3. doi: 10.1002/cncr.34935.
    PubMed     Abstract available
    
    
    May 2023
18. BAEK GT, Huang IJ, Gopal AK
    Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
    Cancer. 2023 May 19. doi: 10.1002/cncr.34816.
    PubMed     Abstract available
    
    
    April 2023
19. JENG LB, Li TC, Wang J, Teng CF, et al
    Increased plasma levels of monocyte chemoattractant protein-1 in patients with hepatitis B virus pre-S2 gene deletion mutation predict a higher risk of hepatocellular carcinoma recurrence after curative surgical resection.
    Cancer. 2023 Apr 25. doi: 10.1002/cncr.34815.
    PubMed     Abstract available
    
    
    
20. YU YC, Paragomi P, Wang R, Liang F, et al
    High serum magnesium is associated with lower risk of hepatocellular carcinoma among patients with nonalcoholic fatty liver disease.
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34799.
    PubMed     Abstract available
    
    
    
21. AN C, Fu Y, Li W, Zuo M, et al
    Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to HAIC.
    Cancer. 2023 Apr 7. doi: 10.1002/cncr.34764.
    PubMed     Abstract available
    
    
    March 2023
22. ABOU-ALFA GK, Wang X, Parrinello CM, Gossai A, et al
    Association between posttreatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma.
    Cancer. 2023 Mar 21. doi: 10.1002/cncr.34754.
    PubMed     Abstract available
    
    
    
23. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
    Reply to "Hepatocellular carcinoma in thalassemia and other hemoglobinopathies".
    Cancer. 2023 Mar 14. doi: 10.1002/cncr.34736.
    PubMed    
    
    
    
24. MANCUSO A, Butera G, Rossi M, Maringhini A, et al
    Hepatocellular carcinoma in thalassemia and other hemoglobinopathies.
    Cancer. 2023 Mar 14. doi: 10.1002/cncr.34735.
    PubMed    
    
    
    January 2023
25. COFFMAN-D'ANNIBALE KL, Greten TF
    Top advances of the year: Hepatobiliary cancers.
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34652.
    PubMed     Abstract available
    
    
    
26. ZHANG J, Huang Q, Yang Y, Zhang J, et al
    A novel prognostic system combining carbonic anhydrase II and preoperative CA19-9 for intrahepatic cholangiocarcinoma after curative resection.
    Cancer. 2023 Jan 10. doi: 10.1002/cncr.34639.
    PubMed     Abstract available
    
    
    
27. ORIGA R, Gianesin B, Longo F, Di Maggio R, et al
    Incidence of cancer and related deaths in hemoglobinopathies: A follow-up of 4631 patients between 1970 and 2021.
    Cancer. 2023;129:107-117.
    PubMed     Abstract available
    
    
    December 2022
28. FU Y, Li X, Yang Z, Li S, et al
    A risk-based post-resection follow-up strategy for hepatocellular carcinoma patients.
    Cancer. 2022 Dec 20. doi: 10.1002/cncr.34601.
    PubMed     Abstract available
    
    
    
29. 
    New assay for early detection of hepatocellular carcinoma.
    Cancer. 2022;128:4176.
    PubMed    
    
    
    November 2022
30. ZHENG Y, Huang N, Kuang S, Zhang J, et al
    The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery.
    Cancer. 2022 Nov 26. doi: 10.1002/cncr.34552.
    PubMed     Abstract available
    
    
    
31. NAKAGAWA M, Inoue M, Ogasawara S, Maruta S, et al
    Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
    Cancer. 2022 Nov 24. doi: 10.1002/cncr.34559.
    PubMed     Abstract available
    
    
    
32. NIERENGARTEN MB
    Blood-based test to predict future risk of developing liver cancer: Researchers recently discovered a genetic signature that can help predict long-term hepatocellular carcinoma risk in patients who have nonalcoholic fatty liver disease, and may also h
    Cancer. 2022;128:3904.
    PubMed    
    
    
    October 2022
33. CAO M, Li H, Sun D, He S, et al
    Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high-risk population: A cross-sectional study.
    Cancer. 2022;128:3653-3662.
    PubMed     Abstract available
    
    
    September 2022
34. LI Y, Liang X, Li H, Chen X, et al
    Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Cancer. 2022 Sep 16. doi: 10.1002/cncr.34457.
    PubMed     Abstract available
    
    
    
35. MATTINGLY TJ 2ND, Shetty K
    The economics of advanced and unresectable hepatocellular carcinoma.
    Cancer. 2022 Sep 15. doi: 10.1002/cncr.34456.
    PubMed    
    
    
    August 2022
36. LEE YT, Singal AG, Lauzon M, Agopian VG, et al
    Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.
    Cancer. 2022 Aug 23. doi: 10.1002/cncr.34436.
    PubMed     Abstract available
    
    
    
37. JALAL PK
    Hepatitis C infection and advanced hepatocellular carcinoma-To treat or not to treat?
    Cancer. 2022 Aug 9. doi: 10.1002/cncr.34408.
    PubMed    
    
    
    July 2022
38. PARIKH ND, Mehta N, Hoteit MA, Yang JD, et al
    Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.
    Cancer. 2022 Jul 7. doi: 10.1002/cncr.34378.
    PubMed     Abstract available
    
    
    May 2022
39. SHORT SS, Kastenberg ZJ, Wei G, Bondoc A, et al
    Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study.
    Cancer. 2022 May 13. doi: 10.1002/cncr.34256.
    PubMed     Abstract available
    
    
    April 2022
40. DE B, Tran Cao HS, Vauthey JN, Manzar GS, et al
    Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States.
    Cancer. 2022 Apr 13. doi: 10.1002/cncr.34223.
    PubMed     Abstract available
    
    
    March 2022
41. LEBECK LEE CM, Ziogas IA, Agarwal R, Alexopoulos SP, et al
    A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.
    Cancer. 2022 Mar 14. doi: 10.1002/cncr.34170.
    PubMed     Abstract available
    
    
    
42. ROBERTS HJ, Wo JY
    Stereotactic body radiation therapy for primary liver tumors: An effective liver-directed therapy in the toolbox.
    Cancer. 2022;128:956-965.
    PubMed     Abstract available
    
    
    January 2022
43. NIERENGARTEN MB
    Aspirin decreases the risk of hepatocellular cancer in at-risk patients.
    Cancer. 2022;128:214-215.
    PubMed    
    
    
    November 2021
44. KATZENSTEIN HM, Malogolowkin MH, Krailo MD, Piao J, et al
    Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Children's Oncology Group study.
    Cancer. 2021 Nov 11. doi: 10.1002/cncr.34014.
    PubMed     Abstract available
    
    
    October 2021
45. DUONG LM, Cai H, Shrubsole MJ, Bailey CE, et al
    Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma.
    Cancer. 2021 Oct 21. doi: 10.1002/cncr.33979.
    PubMed     Abstract available
    
    
    
46. CHENG K, Chen Y, Wang X, Xu M, et al
    Entecavir combined with interferon-alpha is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B.
    Cancer. 2021 Oct 8. doi: 10.1002/cncr.33949.
    PubMed     Abstract available
    
    
    August 2021
47. HARDING JJ, Yang TS, Chen YY, Feng YH, et al
    Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
    Cancer. 2021 Aug 20. doi: 10.1002/cncr.33870.
    PubMed     Abstract available
    
    
    July 2021
48. MERRIAM P, Nathenson MJ
    Liver transplantation for hepatic epithelioid hemangioendothelioma.
    Cancer. 2021 Jul 13. doi: 10.1002/cncr.33751.
    PubMed    
    
    
    
49. DING X, Sun W, Li W, Shen Y, et al
    Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Cancer. 2021 Jul 8. doi: 10.1002/cncr.33677.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.